147 filings
8-K
ONCSQ
ONCOSEC MEDICAL Inc
22 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Bankruptcy or Receivership
5:20pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Departure of Directors or Certain Officers
4:55pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:35pm
8-K
5m0z6ek6lsni878w5ur
16 May 23
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
8:15am
8-K
g0eonjp06s4o4kzpof4
27 Apr 23
Other Events
8:00am
8-K
2dsd88difyp0ebqlmn
11 Apr 23
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
8-K
7taaogp
3 Apr 23
Other Events
7:30am
8-K
z6xoeic sxwv02j2
22 Feb 23
Other Events
8:30am
8-K
ysthkv4
4 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
h7o5y0hr
28 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
gdsm rtb5jdh1lm
27 Dec 22
Departure of Directors or Certain Officers
5:00pm
8-K
wbkikknambbtmc
1 Dec 22
OncoSec Announces Pricing of $3.5 Million Public Offering
4:57pm
8-K
0zs36 finb87d6
29 Nov 22
Entry into a Material Definitive Agreement
8:00am
8-K
goyopwmwook 97o108gr
22 Nov 22
Other Events
5:00pm
8-K
olrbh5a
15 Nov 22
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
5:06pm
8-K
8q1sj5ys5c3rlicium
14 Nov 22
Other Events
6:10am
8-K
8brrwfmy
8 Nov 22
OncoSec Announces Reverse Stock Split
1:15pm
8-K
hqg0q 0w19
17 Oct 22
Departure of Directors or Certain Officers
5:00pm